Conjugated estrogens

Not to be confused with Estrogen conjugate or Esterified estrogens.

Conjugated estrogens

Estrone sulfate, the primary active component in conjugated estrogens (constitutes about 50 to 70% of total content)
Equilin sulfate, the second most major active component in conjugated estrogens (constitutes about 20 to 30% of total content)
Combination of
Estrone sulfate	Estrogen
Equilin sulfate	Estrogen
17α-Dihydro-equilin sulfate	Estrogen
Clinical data
Trade names	Cenestin, Enjuvia, Premarin, others
Other names	CEs; Conjugated equine estrogens; CEEs; Pregnant mares' urine; Estrogens, conjugated
AHFS/Drugs.com	Multum Consumer Information
Routes of administration	By mouth, topical, vaginal, intravenous injection, intramuscular injection [1] [2]
Drug class	Estrogen
ATC code	G03CA57 ( WHO )
Legal status
Legal status	US: WARNING [3] In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	Variable [4]
Protein binding	High (to albumin and SHBG Tooltip sex hormone-binding globulin) [4] [1]
Metabolism	Liver [4] [1]
Elimination half-life	Estrone: 26.7 hours Estrone (BA): 14.8 hours Equilin: 11.4 hours [5] [ unreliable medical source? ]
Excretion	Kidney [4]
Identifiers
CAS Number	12126-59-9  Y
PubChem CID	656613
DrugBank	DB00286
ChemSpider	570974  Y
UNII	IU5QR144QX
KEGG	D04070
ChEBI	CHEBI:8389
ChEMBL	ChEMBL1201649
CompTox Dashboard (EPA)	DTXSID9021186
ECHA InfoCard	100.031.987
(verify)

Conjugated estrogens (CEs), or conjugated equine estrogens (CEEs), sold under the brand name Premarin among others, is an estrogen medication which is used in menopausal hormone therapy and for various other indications. ^{[6] [4] [1] [7]} It is a mixture of the sodium salts of estrogen conjugates found in horses, such as estrone sulfate and equilin sulfate. ^{[1] [7] [6]} CEEs are available in the form of both natural preparations manufactured from the urine of pregnant mares and fully synthetic replications of the natural preparations. ^{[8] [9]} They are formulated both alone and in combination with progestins such as medroxyprogesterone acetate. ^[6] CEEs are usually taken by mouth, but can also be given by application to the skin or vagina as a cream or by injection into a blood vessel or muscle. ^{[1] [2]}

Side effects of CEEs include breast tenderness and enlargement, headache, fluid retention, and nausea among others. ^{[4] [1]} It may increase the risk of endometrial hyperplasia and endometrial cancer in women with an intact uterus if it is not taken together with a progestogen like progesterone. ^{[4] [1]} The medication may also increase the risk of blood clots, cardiovascular disease, and, when combined with most progestogens, breast cancer. ^[10] CEEs are estrogens, or agonists of the estrogen receptor, the biological target of estrogens like estradiol. ^{[1] [4]} Compared to estradiol, certain estrogens in CEEs are more resistant to metabolism, and the medication shows relatively increased effects in certain parts of the body like the liver. ^[1] This results in an increased risk of blood clots and cardiovascular problems with CEEs relative to estradiol. ^{[1] [11]}

Premarin, the major brand of CEEs in use, is manufactured by Pfizer and was first marketed in 1941 in Canada and in 1942 in the United States. ^[7] It is the most commonly used form of estrogen in menopausal hormone therapy in the United States. ^{[12] [13]} However, it has begun to fall out of favor relative to bioidentical estradiol, which is the most widely used form of estrogen in Europe for menopausal hormone therapy. ^{[13] [14] [15] [16]} CEEs are available widely throughout the world. ^[6] An estrogen preparation very similar to CEEs but differing in source and composition is esterified estrogens. ^[1] In 2020, it was the 283rd most commonly prescribed medication in the United States, with more than 1 million prescriptions. ^{[17] [18]}

Medical uses

CEEs are a form of hormone therapy used in women. ^[19] It is used most commonly in postmenopausal women who have had a hysterectomy to treat hot flashes, and burning, itching, and dryness of the vagina and surrounding areas. ^[20] It must be used in combination with a progestogen in women who have not had a hysterectomy. ^[1] For women already taking the medication, it can be used to treat osteoporosis, although it is not recommended solely for this use. ^[21] Some lesser known uses are as a means of high-dose estrogen therapy in the treatment of breast cancer in both women and men and in the treatment of prostate cancer in men. ^{[22] [23]} It has been used at a dosage of 2.5 mg three times per day (7.5 mg/day total) for prostate cancer. ^{[24] [25]}

CEEs are specifically approved in countries such as the United States and Canada for the treatment of moderate to severe vasomotor symptoms (hot flashes) and vulvovaginal atrophy (atrophic vaginitis, atrophic urethritis) associated with menopause, hypoestrogenism due to hypogonadism, ovariectomy, or primary ovarian failure, abnormal uterine bleeding, the palliative treatment of metastatic breast cancer in women, the palliative treatment of advanced androgen-dependent prostate cancer in men, and the prevention of postmenopausal osteoporosis. ^{[5] [26] [6]} The intravenous formulation of CEEs is specifically used to rapidly limit bleeding in women with hemorrhage due to dysfunctional uterine bleeding. ^{[2] [27] : 318  [28] : 60}

• v
• t
• e

Estrogen dosages for menopausal hormone therapy

Route/form	Estrogen	Low	Standard	High
Oral	Estradiol	0.5–1 mg/day	1–2 mg/day	2–4 mg/day
	Estradiol valerate	0.5–1 mg/day	1–2 mg/day	2–4 mg/day
	Estradiol acetate	0.45–0.9 mg/day	0.9–1.8 mg/day	1.8–3.6 mg/day
	Conjugated estrogens	0.3–0.45 mg/day	0.625 mg/day	0.9–1.25 mg/day
	Esterified estrogens	0.3–0.45 mg/day	0.625 mg/day	0.9–1.25 mg/day
	Estropipate	0.75 mg/day	1.5 mg/day	3 mg/day
	Estriol	1–2 mg/day	2–4 mg/day	4–8 mg/day
	Ethinylestradiol a	2.5–10 μg/day	5–20 μg/day	–
Nasal spray	Estradiol	150 μg/day	300 μg/day	600 μg/day
Transdermal patch	Estradiol	25 μg/dayb	50 μg/dayb	100 μg/dayb
Transdermal gel	Estradiol	0.5 mg/day	1–1.5 mg/day	2–3 mg/day
Vaginal	Estradiol	25 μg/day	–	–
	Estriol	30 μg/day	0.5 mg 2x/week	0.5 mg/day
IM Tooltip Intramuscular or SC injection	Estradiol valerate	–	–	4 mg 1x/4 weeks
	Estradiol cypionate	1 mg 1x/3–4 weeks	3 mg 1x/3–4 weeks	5 mg 1x/3–4 weeks
	Estradiol benzoate	0.5 mg 1x/week	1 mg 1x/week	1.5 mg 1x/week
SC implant	Estradiol	25 mg 1x/6 months	50 mg 1x/6 months	100 mg 1x/6 months
Footnotes:a = No longer used or recommended, due to health concerns. b = As a single patch applied once or twice per week (worn for 3–4 days or 7 days), depending on the formulation. Note: Dosages are not necessarily equivalent. Sources: See template.

Available forms

See also: Conjugated estrogens/medroxyprogesterone acetate, Conjugated estrogens/norgestrel, Conjugated estrogens/methyltestosterone, and Conjugated estrogens/bazedoxifene

Natural CEEs, as Premarin, are available in the form of oral tablets (0.3 mg, 0.625 mg, 0.9 mg, 1.25 mg, or 2.5 mg), creams for topical or vaginal administration (0.625 mg/g), and vials for intravenous or intramuscular injection (25 mg/vial). ^{[2] [29]} Synthetic CEEs, such as Cenestin (Synthetic A), Enjuvia (Synthetic B), and generic formulations, are available in the form of oral tablets (0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, or 1.25 mg) and creams for topical or vaginal administration (0.625 mg/g). ^{[2] [30]}

Contraindications

See also: Estrogen (medication) § Contraindications

Contraindications of CEEs include breast cancer and a history of venous thromboembolism, among others.^{[ citation needed ]}

Side effects

The most common side effects associated with CEEs are vaginal yeast infections, vaginal spotting or bleeding, painful menses, and cramping of the legs. While there are some contradictory data, estrogen alone does not appear to increase the risk of coronary heart disease or breast cancer, unlike the case of estrogen in combination with certain progestins such as levonorgestrel or medroxyprogesterone acetate. ^[31] Only a few clinical studies have assessed differences between oral CEEs and oral estradiol in terms of health parameters. ^[32] Oral CEEs have been found to possess a significantly greater risk of thromboembolic and cardiovascular complications than oral estradiol (OR Tooltip Odds ratio = 2.08) and oral esterified estrogens (OR Tooltip Odds ratio = 1.78). ^{[32] [33] [34]} However, in another study, the increase in venous thromboembolism risk with oral CEEs plus medroxyprogesterone acetate and oral estradiol plus norethisterone acetate was found to be equivalent (RR Tooltip Relative risk = 4.0 and 3.9, respectively). ^{[35] [36]} As of present, there are no randomized controlled trials that would allow for unambiguous conclusions. ^[32]

• v
• t
• e

Results of the Women's Health Initiative (WHI) menopausal hormone therapy randomized controlled trials

Clinical outcome	Hypothesized effect on risk	Estrogen and progestogen (CEs Tooltip conjugated estrogens 0.625 mg/day p.o. + MPA Tooltip medroxyprogesterone acetate 2.5 mg/day p.o.) (n = 16,608, with uterus, 5.2–5.6 years follow up)			Estrogen alone (CEs Tooltip Conjugated estrogens 0.625 mg/day p.o.) (n = 10,739, no uterus, 6.8–7.1 years follow up)
		HR Tooltip Hazard ratio	95% CI Tooltip Confidence interval	AR Tooltip Attributable risk	HR Tooltip Hazard ratio	95% CI Tooltip Confidence interval	AR Tooltip Attributable risk
Coronary heart disease	Decreased	1.24	1.00–1.54	+6 / 10,000 PYs	0.95	0.79–1.15	−3 / 10,000 PYs
Stroke	Decreased	1.31	1.02–1.68	+8 / 10,000 PYs	1.37	1.09–1.73	+12 / 10,000 PYs
Pulmonary embolism	Increased	2.13	1.45–3.11	+10 / 10,000 PYs	1.37	0.90–2.07	+4 / 10,000 PYs
Venous thromboembolism	Increased	2.06	1.57–2.70	+18 / 10,000 PYs	1.32	0.99–1.75	+8 / 10,000 PYs
Breast cancer	Increased	1.24	1.02–1.50	+8 / 10,000 PYs	0.80	0.62–1.04	−6 / 10,000 PYs
Colorectal cancer	Decreased	0.56	0.38–0.81	−7 / 10,000 PYs	1.08	0.75–1.55	+1 / 10,000 PYs
Endometrial cancer	–	0.81	0.48–1.36	−1 / 10,000 PYs	–	–	–
Hip fractures	Decreased	0.67	0.47–0.96	−5 / 10,000 PYs	0.65	0.45–0.94	−7 / 10,000 PYs
Total fractures	Decreased	0.76	0.69–0.83	−47 / 10,000 PYs	0.71	0.64–0.80	−53 / 10,000 PYs
Total mortality	Decreased	0.98	0.82–1.18	−1 / 10,000 PYs	1.04	0.91–1.12	+3 / 10,000 PYs
Global index	–	1.15	1.03–1.28	+19 / 10,000 PYs	1.01	1.09–1.12	+2 / 10,000 PYs
Diabetes	–	0.79	0.67–0.93		0.88	0.77–1.01
Gallbladder disease	Increased	1.59	1.28–1.97		1.67	1.35–2.06
Stress incontinence	–	1.87	1.61–2.18		2.15	1.77–2.82
Urge incontinence	–	1.15	0.99–1.34		1.32	1.10–1.58
Peripheral artery disease	–	0.89	0.63–1.25		1.32	0.99–1.77
Probable dementia	Decreased	2.05	1.21–3.48		1.49	0.83–2.66
Abbreviations: CEs = conjugated estrogens. MPA = medroxyprogesterone acetate. p.o. = per oral. HR = hazard ratio. AR = attributable risk. PYs = person–years. CI = confidence interval. Notes: Sample sizes (n) include placebo recipients, which were about half of patients. "Global index" is defined for each woman as the time to earliest diagnosis for coronary heart disease, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer (estrogen plus progestogen group only), hip fractures, and death from other causes. Sources: See template.

• v
• t
• e

Risk of venous thromboembolism (VTE) with hormone therapy and birth control (QResearch/CPRD)

Type	Route	Medications	Odds ratio (95% CI Tooltip confidence interval)
Menopausal hormone therapy	Oral	Estradiol alone     ≤1 mg/day     >1 mg/day	1.27 (1.16–1.39)* 1.22 (1.09–1.37)* 1.35 (1.18–1.55)*
		Conjugated estrogens alone     ≤0.625 mg/day     >0.625 mg/day	1.49 (1.39–1.60)* 1.40 (1.28–1.53)* 1.71 (1.51–1.93)*
		Estradiol/medroxyprogesterone acetate	1.44 (1.09–1.89)*
		Estradiol/dydrogesterone     ≤1 mg/day E2     >1 mg/day E2	1.18 (0.98–1.42) 1.12 (0.90–1.40) 1.34 (0.94–1.90)
		Estradiol/norethisterone     ≤1 mg/day E2     >1 mg/day E2	1.68 (1.57–1.80)* 1.38 (1.23–1.56)* 1.84 (1.69–2.00)*
		Estradiol/norgestrel or estradiol/drospirenone	1.42 (1.00–2.03)
		Conjugated estrogens/medroxyprogesterone acetate	2.10 (1.92–2.31)*
		Conjugated estrogens/norgestrel     ≤0.625 mg/day CEEs     >0.625 mg/day CEEs	1.73 (1.57–1.91)* 1.53 (1.36–1.72)* 2.38 (1.99–2.85)*
		Tibolone alone	1.02 (0.90–1.15)
		Raloxifene alone	1.49 (1.24–1.79)*
	Transdermal	Estradiol alone    ≤50 μg/day    >50 μg/day	0.96 (0.88–1.04) 0.94 (0.85–1.03) 1.05 (0.88–1.24)
		Estradiol/progestogen	0.88 (0.73–1.01)
	Vaginal	Estradiol alone	0.84 (0.73–0.97)
		Conjugated estrogens alone	1.04 (0.76–1.43)
Combined birth control	Oral	Ethinylestradiol/norethisterone	2.56 (2.15–3.06)*
		Ethinylestradiol/levonorgestrel	2.38 (2.18–2.59)*
		Ethinylestradiol/norgestimate	2.53 (2.17–2.96)*
		Ethinylestradiol/desogestrel	4.28 (3.66–5.01)*
		Ethinylestradiol/gestodene	3.64 (3.00–4.43)*
		Ethinylestradiol/drospirenone	4.12 (3.43–4.96)*
		Ethinylestradiol/cyproterone acetate	4.27 (3.57–5.11)*
Notes: (1) Nested case–control studies (2015, 2019) based on data from the QResearch and Clinical Practice Research Datalink (CPRD) databases. (2) Bioidentical progesterone was not included, but is known to be associated with no additional risk relative to estrogen alone. Footnotes: * = Statistically significant (p < 0.01). Sources: See template.

Overdose

See also: Estrogen (medication) § Overdose

Estrogens, including CEEs, are relatively safe in acute overdose.^{[ citation needed ]}

Interactions

See also: Estrogen (medication) § Interactions

Inhibitors and inducers of cytochrome P450 enzymes may interact with CEEs.^{[ citation needed ]}

Pharmacology

Pharmacodynamics

See also: Pharmacodynamics of estradiol

Estradiol, the main active form of estrone sulfate and the major active estrogen with CEEs

17β-Dihydroequilin, the main active form of equilin sulfate and the second major active estrogen with CEEs

CEEs are a combination of estrogens, or agonists of the estrogen receptors. ^[1] The major estrogen in CEEs, sodium estrone sulfate, itself is inactive, and rather serves as a prodrug of estrone and then of estradiol. ^{[1] [37] [38]} The transformation of estrone sulfate to estrone is catalyzed by steroid sulfatase, and of estrone into estradiol by 17β-hydroxysteroid dehydrogenase. ^{[1] [39]} CEEs (as Premarin) and estrone have been found to be equivalent in potency in an animal model of estrogenic activity. ^[7] On the other hand, the active forms of the equine estrogens in CEEs, such as equilin and 17β-dihydroequilin, have greater potency in the liver relative to bioidentical estradiol, similarly to synthetic estrogens like ethinylestradiol and diethylstilbestrol. ^[1] This results in disproportionate effects on liver protein production compared to estradiol, although to a lesser extent than ethinylestradiol and diethylstilbestrol. ^[1] In addition, 17β-dihydroequilenin has shown a selective estrogen receptor modulator (SERM)-like profile of estrogenic activity in studies with monkeys, in which beneficial effects on bone and the cardiovascular system were observed but proliferative responses in breast or endometrium were not seen, although the clinical significance of this is unknown. ^[40]

CEEs consists of the sodium salts of the sulfate esters of equine estrogens in a specific and consistent composition (see the table). ^{[1] [7]} The major estrogens in CEEs are sodium estrone sulfate and sodium equilin sulfate, which together account for approximately 71.5–92.0% of the total content of CEEs. ^{[6] [1] [7]} CEEs are prodrugs of the active forms of the estrogens. ^{[1] [7] [6]} Sodium estrone sulfate is a prodrug of estrone, which in turn is a prodrug of estradiol, while sodium equilin sulfate is a prodrug of equilin and then of 17β-dihydroequilin. ^[1] As such, the major active estrogens with CEEs are estradiol and 17β-dihydroequilin, which have potent estrogenic activity and account for most of the effects of CEEs. ^[1] The 17α-estrogens in CEEs such as 17α-estradiol and 17α-dihydroequilin have low estrogenicity and are thought to contribute minimally to its effects. ^[1] There are many different steroids in natural CEE products like Premarin, as many as 230 compounds and including even androgens and progestogens, but only the estrogens are present in sufficient amounts to produce clinically-relevant effects. ^{[7] [41] [12]}

A dosage of 0.625 mg/day oral CEEs has been found to increase SHBG levels by 100%. ^{[41] [42]} For comparison, 1 mg/day oral estradiol increased SHBG levels by 45%, while 50 μg/day transdermal estradiol increased SHBG levels by 12%. ^{[41] [42]} Ethinylestradiol is more potent in its effects on liver protein synthesis than either CEEs or estradiol, with 10 μg/day oral ethinylestradiol having been found to be approximately equivalent to 1.25 mg/day CEEs. ^[41]

• v
• t
• e

Composition of conjugated estrogens and properties of constituents

Compound	Synonym	Proportion (%)	Relative potency in the vagina (%)	Relative potency in the uterus (%)	RBA Tooltip Relative binding affinity for ERα (%)	RBA for ERβ (%)	ERα / ERβ RBA ratio
Conjugated estrogens	–	100	38	100	–	–	–
Estrone	–	49.1–61.5	30	32	26	52	0.50
Equilin	Δ7-Estrone	22.4–30.5	42	80	13	49	0.26
17α-Dihydroequilin	Δ7-17α-Estradiol	13.5–19.5	0.06	2.6	41	32	1.30
17α-Estradiol	–	2.5–9.5	0.11	3.5	19	42	0.45
Δ8-Estrone	–	3.5–3.9	?	?	19	32	0.60
Equilenin	Δ6,8-Estrone	2.2–2.8	1.3	11.4	15	20–29	0.50–0.75
17β-Dihydroequilin	Δ7-17β-Estradiol	0.5–4.0	83	200	113	108	1.05
17α-Dihydroequilenin	Δ6,8-17α-Estradiol	1.2–1.6	0.018	1.3	20	49	0.40
17β-Estradiol	–	0.56–0.9	100	?	100	100	1.00
17β-Dihydroequilenin	Δ6,8-17β-Estradiol	0.5–0.7	0.21	9.4	68	90	0.75
Δ8-17β-Estradiol	–	Small amounts	?	?	68	72	0.94
Notes: All listed compounds are present in conjugated estrogen products specifically in the form of the sodium salts of the sulfate esters (i.e., as sodium estrone sulfate, sodium equilin sulfate, etc.). Sources: See template.

• v
• t
• e

Potencies of oral estrogens ^{[data sources 1]}

Compound	Dosage for specific uses (mg usually) [lower-alpha 1]
	ETD [lower-alpha 2]	EPD [lower-alpha 2]	MSD [lower-alpha 2]	MSD [lower-alpha 3]	OID [lower-alpha 3]	TSD [lower-alpha 3]
Estradiol (non-micronized)	30	≥120–300	120	6	-	-
Estradiol (micronized)	6–12	60–80	14–42	1–2	>5	>8
Estradiol valerate	6–12	60–80	14–42	1–2	-	>8
Estradiol benzoate	-	60–140	-	-	-	-
Estriol	≥20	120–150 [lower-alpha 4]	28–126	1–6	>5	-
Estriol succinate	-	140–150 [lower-alpha 4]	28–126	2–6	-	-
Estrone sulfate	12	60	42	2	-	-
Conjugated estrogens	5–12	60–80	8.4–25	0.625–1.25	>3.75	7.5
Ethinylestradiol	200 μg	1–2	280 μg	20–40 μg	100 μg	100 μg
Mestranol	300 μg	1.5–3.0	300–600 μg	25–30 μg	>80 μg	-
Quinestrol	300 μg	2–4	500 μg	25–50 μg	-	-
Methylestradiol	-	2	-	-	-	-
Diethylstilbestrol	2.5	20–30	11	0.5–2.0	>5	3
DES dipropionate	-	15–30	-	-	-	-
Dienestrol	5	30–40	42	0.5–4.0	-	-
Dienestrol diacetate	3–5	30–60	-	-	-	-
Hexestrol	-	70–110	-	-	-	-
Chlorotrianisene	-	>100	-	-	>48	-
Methallenestril	-	400	-	-	-	-
Sources and footnotes: [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] Dosages are given in milligrams unless otherwise noted. Dosed every 2 to 3 weeks Dosed daily In divided doses, 3x/day; irregular and atypical proliferation.

• v
• t
• e

Relative oral potencies of estrogens

Estrogen	HF Tooltip Hot flashes	VE Tooltip Vaginal epithelium	UCa Tooltip Urinary calcium	FSH Tooltip Follicle-stimulating hormone	LH Tooltip Luteinizing hormone	HDL Tooltip High-density lipoprotein-C Tooltip Cholesterol	SHBG Tooltip Sex hormone-binding globulin	CBG Tooltip Corticosteroid-binding globulin	AGT Tooltip Angiotensinogen	Liver
Estradiol	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Estrone	?	?	?	0.3	0.3	?	?	?	?	?
Estriol	0.3	0.3	0.1	0.3	0.3	0.2	?	?	?	0.67
Estrone sulfate	?	0.9	0.9	0.8–0.9	0.9	0.5	0.9	0.5–0.7	1.4–1.5	0.56–1.7
Conjugated estrogens	1.2	1.5	2.0	1.1–1.3	1.0	1.5	3.0–3.2	1.3–1.5	5.0	1.3–4.5
Equilin sulfate	?	?	1.0	?	?	6.0	7.5	6.0	7.5	?
Ethinylestradiol	120	150	400	60–150	100	400	500–600	500–600	350	2.9–5.0
Diethylstilbestrol	?	?	?	2.9–3.4	?	?	26–28	25–37	20	5.7–7.5
Sources and footnotes Notes: Values are ratios, with estradiol as standard (i.e., 1.0). Abbreviations:HF = Clinical relief of hot flashes. VE = Increased proliferation of vaginal epithelium. UCa = Decrease in UCa Tooltip urinary calcium. FSH = Suppression of FSH Tooltip follicle-stimulating hormone levels. LH = Suppression of LH Tooltip luteinizing hormone levels. HDL-C, SHBG, CBG, and AGT = Increase in the serum levels of these liver proteins. Liver = Ratio of liver estrogenic effects to general/systemic estrogenic effects (hot flashes/gonadotropins). Sources: See template.

Antigonadotropic effects

Testosterone levels with no treatment and with various estrogens in men with prostate cancer. Determinations were made with an early radioimmunoassay (RIA).

A preliminary study of ovulation inhibition in women found that oral CEEs was 33% effective at 1.25 mg/day and 94% at 3.75 mg/day. ^{[63] [64]} A dosage of oral CEEs of 2.5 mg three times daily (7.5 mg/day total) has been found to suppress total testosterone levels in men to an equivalent extent as 3 mg/day oral diethylstilbestrol, which is the minimum dosage of diethylstilbestrol required to consistently suppress total testosterone levels into the castrate range (<50 ng/dL). ^[65]

Pharmacokinetics

See also: Pharmacokinetics of estradiol

CEEs are hydrolyzed in the intestines during first-pass metabolism upon oral administration. ^{[66] [6]} Following their absorption, they are resulfated mainly in the liver also during the first pass. ^[66] Following this, they serve as a circulating reservoir and are slowly rehydrolyzed into their unconjugated active forms. ^[66]

Oral CEEs, at a daily dosage of 0.625 mg, achieve estrone and estradiol levels of 150 pg/mL and 30–50 pg/mL, respectively, while a daily oral dosage of 1.25 mg achieves levels of 120–200 pg/mL and 40–60 pg/mL of estrone and estradiol, respectively. ^[67] The oral ingestion of 10 mg CEEs, which contains about 4.5 mg sodium estrone sulfate and 2.5 mg sodium equilin sulfate, produces maximal plasma concentrations of estrone and equilin of 1,400 pg/mL and 560 pg/mL within three and five hours, respectively. ^[67] By 24 hours post-dose of 10 mg, the levels of estrone and equilin fall to 280 pg/mL and 125 pg/mL, respectively. ^[67] Oral CEEs 1.25 mg/daily and oral micronized estradiol 1 mg/daily result in similar plasma concentrations of estrone and estradiol (150–300 pg/mL and 30–50 pg/mL for micronized estradiol, respectively) (oral estradiol is extensively metabolized into estrone during hepatic first-pass metabolism), ^[67] although this does not account for equilin and other equine estrogens involved in the effects of CEEs, which may be significantly more potent in comparison to estrone. ^{[68] [69]} The pharmacokinetics of vaginal CEEs ^[70] and of intravenous CEEs have been studied as well. ^[71]

Eoncentrations of equilin that are very high relative to those of other estrogens are produced by typical clinical doses of CEEs. ^[72] With a dosage of 1.25 mg oral CEEs, equilin levels of 1,082 to 2,465 pg/mL have been observed. ^[72] The clinical significance of these levels of equilin is unknown. ^[72]

The active forms are metabolized primarily in the liver. ^[6] There is some enterohepatic recirculation of CEEs. ^[6] Following a single oral dose of 0.625 CEEs, the biological half-life of estrone was 26.7 hours, of baseline-adjusted estrone was 14.8 hours, and of equilin was 11.4 hours. ^{[5] [ unreliable medical source? ]}

• v
• t
• e

Plasma estrogen levels after a single dose of conjugated estrogens by different routes

Route	Dose	Time	E2 (↑Δ)	E1 (↑Δ)	Ratio
Oral	0.3 mg 0.625 mg 1.25 mg 1.25 mg 2.5 mg	6 hours 6 hours 6 hours 1 hour 6 hours	+20 pg/mL +50 pg/mL +70 pg/mL +35–58 pg/mL +160 pg/mL	ND ND ND 110 pg/mL ND	ND ND ND 0.32–0.52 ND
Vaginal (cream)	0.3 mg 0.625 mg 0.625 mg 1.25 mg 1.25 mg 2.5 mg	ND ND ND 2 hours ND ND	+4 pg/mL +13–29 pg/mL +17 pg/mL +25 pg/mL +27 pg/mL +32 pg/mL	+20 pg/mL +29–55 pg/mL +45 pg/mL +50 pg/mL +110 pg/mL +40 pg/mL	0.2 0.24–1.0 0.38 0.5 0.25 0.8
Intravenous a	20 mg	5 min 30 min 60 min 120 min	800 pg/mL 3000 pg/mL 3500 pg/mL 3100 pg/mL	4500 pg/mL 24000 pg/mL 19000 pg/mL 10500 pg/mL	1:5.3 1:8.1 1:5.5 1:3.4
Notes:a = Absolute levels, not change. Sources: See template.

• v
• t
• e

Protein binding and metabolic clearance rates of estrogens

Compound	RBA Tooltip Relative binding affinity to SHBG Tooltip sex hormone-binding globulin (%)	Bound to SHBG (%)	Bound to albumin (%)	Total bound (%)	MCR Tooltip Metabolic clearance rate (L/day/m2)
17β-Estradiol	50	37	61	98	580
Estrone	12	16	80	96	1050
Estriol	0.3	1	91	92	1110
Estrone sulfate	0	0	99	99	80
17β-Dihydroequilin	30	?	?	?	1250
Equilin	8	26	13	?	2640
17β-Dihydroequilin sulfate	0	?	?	?	375
Equilin sulfate	0	?	?	?	175
Δ8-Estrone	?	?	?	?	1710
Notes:RBA for SHBG (%) is compared to 100% for testosterone. Sources: See template.

Chemistry

See also: List of estrogens, Estrogen ester, and Estrogen conjugate

CEEs are naturally occurring estrane steroids. ^{[1] [7]} They are in conjugate form, as the sodium salts of the C17β sulfate esters. ^{[1] [7]} The estrogens in CEEs, in their unconjugated active forms, include bioidentical human estrogens like estradiol and estrone as well as equine-specific estrogens such as equilin and 17β-dihydroequilin. ^{[1] [7]} The equine estrogens differ from human estrogens in that they have additional double bonds in the B ring of the steroid nucleus. ^{[1] [7]} CEEs contain both 17β-estrogens like estradiol and 17β-dihydroequilin and the C17α epimers like 17α-estradiol and 17α-dihydroequilin. ^{[1] [7]}

v t e Chemical structures of equine estrogens [12] [73] Estrone 17β-Estradiol 17α-Estradiol Equilin 17β-Dihydroequilin 17α-Dihydroequilin Equilenin 17β-Dihydroequilenin 17α-Dihydroequilenin Δ8-Estrone Δ8-17β-Estradiol This diagram illustrates the chemical structures of the active/unconjugated forms of the equine estrogens present in conjugated estrogens.

History

Conjugated estriol, an extract of the urine of pregnant women and sold under the brand names Progynon and Emmenin in the 1930s, was the predecessor of Premarin. ^[74] Both of these products contained conjugated estrogens similarly to Premarin, but the estrogens were human estrogens as opposed to equine estrogens and the composition differed. The major active ingredient in Progynon and Emmenin was estriol glucuronide.

Estrone sulfate was first isolated from the urine of pregnant mares in the late 1930s by researchers in the Department of Biochemistry at University of Toronto. ^[75] Premarin was first introduced in 1941 by Wyeth Ayerst as a treatment for hot flashes and other symptoms of menopause; at that time, Wyeth Ayerst only had to prove its safety, and not its efficacy. ^[76] In response to the 1962 Kefauver Harris Amendment the FDA had its efficacy reviewed, and in 1972 found it effective for menopausal symptoms and probably effective for osteoporosis. ^[77] The review also determined that two estrogens – estrone sulfate and equilin sulfate – were primarily responsible for the activity of Premarin, and it laid the groundwork for Abbreviated New Drug Application (ANDA) submissions of generic versions. ^[76] In 1984 an NIH consensus panel found that estrogens were effective for preventing osteoporosis ^[78] and 1986 the FDA announced in the Federal Register that Premarin was effective for preventing osteoporosis. ^[79] This announcement led to a rapid growth in sales, and interest from generic manufacturers to introduce generic versions. ^[76]

Conjugated estrogens was introduced for medical use under the brand name Premarin in Canada in 1941, in the United States in 1942, and in the United Kingdom in 1956. ^[80]

The manufacturer of Premarin secretly paid gynecologist Robert A. Wilson to promote its use by menopausal women in his 1966 book, Feminine Forever , leading to increased sales. ^[81]

Society and culture

Names

Estrogens, conjugated is the generic name of the drug and its USP Tooltip United States Pharmacopeia and JAN Tooltip Japanese Accepted Name. ^[82] It is also known as conjugated estrogens or as conjugated equine estrogens. ^{[5] [ unreliable medical source? ]} The brand name Premarin is a contraction of "pregnant mares' urine". ^{[83] [84] [85]}

CEEs are marketed under a large number of brand names throughout the world. ^[6] The major brand name of the natural form of CEEs manufactured from the urine of pregnant mares is Premarin. ^[6] Major brand names of fully synthetic versions of CEEs include Cenestin and Enjuvia in the United States and C.E.S. and Congest in Canada. ^{[6] [8] [9]} CEEs are also formulated in combination with progestins. ^[6] Major brand names of CEEs in combination with medroxyprogesterone acetate include Prempro and Premphase in the United States, Premplus in Canada, Premique in the United Kingdom and Ireland, Premia in Australia and New Zealand, and Premelle in South Africa. ^{[6] [86]} Prempak-C is a combination of CEEs and norgestrel which is used in the United Kingdom and Ireland, and Prempak N is a combination of CEEs and medrogestone which is used in South Africa. ^[6] Many of the aforementioned brand names are also used in other, non-English-speaking countries. ^[6]

Availability

See also: List of estrogens available in the United States

CEEs are marketed and available widely throughout the world. ^{[6] [26]} This includes in all English-speaking countries, throughout the European Union, Latin America, Asia, and elsewhere in the world. ^{[6] [26]}

Health effects

Research starting in 1975 showed substantially increased risk of endometrial cancer. ^{[87] [88]} Since 1976, the drug has carried a label warning about the risk. ^[89] As part of the Women's Health Initiative sponsored by the National Institutes of Health, a large-scale clinical trial of menopausal HRT showed that long-term use of estrogen and a progestin may increase the risk of strokes, heart attacks, blood clots, and breast cancer. ^[90] Following these results, Wyeth experienced a significant decline in its sales of Premarin, Prempro (CEEs and medroxyprogesterone acetate), and related products, from over $2 billion in 2002 to just over $1 billion in 2006. ^[91]

Litigation

This drug has been the subject of litigation; more than 13,000 people have sued Wyeth between 2002 and 2009. Wyeth and Pharmacia & Upjohn prevailed in the vast majority of hormone therapy cases previously set for trial through a combination of rulings by judges, verdicts by juries, and dismissals by plaintiffs themselves. ^[92] Of the company's losses, two of the jury verdicts were reversed post-trial and others are being challenged on appeal. Wyeth also won five summary judgments on Prempro cases and had 15 cases voluntarily dismissed by plaintiffs. The company won dismissals in another 3,000 cases. ^[93] In 2006, Mary Daniel, in a trial in Philadelphia, was awarded $1.5 million in compensatory damages as well as undisclosed punitive damages. As of 2010, Wyeth had won the last four of five cases, most recently in Virginia, finding that they were not responsible for the breast cancer of plaintiff Georgia Torkie-Tork. ^[94] Wyeth has been quoted as saying "many risk factors associated with breast cancer have been identified, but science cannot establish what role any particular risk factor or combination play in any individual woman's breast cancer." ^[95] Wyeth's counsel in the case also noted that in the WHI trial, 99.62% of women took the drug and "did not get breast cancer". ^[93]

Animal welfare

Animal welfare groups claim that animal husbandry and urine collection methods used in the production of CEEs cause undue stress and suffering to the mares involved. Animal activists have made claims of abuses ranging from inadequate stall size, long periods of confinement, cumbersome urine collection, and continuous breeding cycles. After reaching advanced age, many of the mares are adopted for recreation use, while some are sent to feed lots for slaughter. Despite the controversy, the USDA called the CEEs HRT industry a model of self-regulation. ^[96]

References

1. Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID   16112947. S2CID   24616324.
2. "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 19 February 2018.
3. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
4. "PREMARIN- estrogens, conjugated tablet, film coated Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc". labeling.pfizer.com. Retrieved 3 June 2019.
5. "Conjugated estrogens".
6. Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. p. 2087. ISBN   978-0-85369-840-1.
7. Fritz MA, Speroff L (28 March 2012). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 751–3. ISBN   978-1-4511-4847-3.
8. Moscou K, Snipe K (1 December 2012). Pharmacology for Pharmacy Technicians Pageburst E-Book on VitalSource2: Pharmacology for Pharmacy Technicians Pageburst E-Book on VitalSource. Elsevier Health Sciences. pp. 573–. ISBN   978-0-323-08578-6.
9. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, World Health Organization, International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 378–. ISBN   978-92-832-1291-1.
10. Pickar JH, Archer DF, Kagan R, Pinkerton JV, Taylor HS (August 2017). "Safety and benefit considerations for menopausal hormone therapy". Expert Opinion on Drug Safety. 16 (8): 941–954. doi:10.1080/14740338.2017.1343298. PMID   28664754. S2CID   24155838.
11. Scarabin PY (December 2014). "Hormones and venous thromboembolism among postmenopausal women". Climacteric. 17 (Suppl 2): 34–37. doi:10.3109/13697137.2014.956717. PMID   25223916. S2CID   5084606.
12. Bhavnani BR, Stanczyk FZ (July 2014). "Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action". J. Steroid Biochem. Mol. Biol. 142: 16–29. doi:10.1016/j.jsbmb.2013.10.011. PMID   24176763.
13. Quereda F (2017). "Hormone Therapy (I): Estrogens, Progestogens, and Androgens". Menopause. Springer. pp. 181–196. doi:10.1007/978-3-319-59318-0_11. ISBN   978-3-319-59317-3.
14. L'Hermite M (August 2017). "Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal". Climacteric. 20 (4): 331–338. doi:10.1080/13697137.2017.1291607. PMID   28301216. S2CID   4771048.
15. Simon JA (July 2014). "What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead?". Menopause. 21 (7): 769–783. doi:10.1097/GME.0000000000000169. PMID   24398406. S2CID   30292136.
16. Holtorf K (January 2009). "The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?". Postgraduate Medicine. 121 (1): 73–85. doi:10.3810/pgm.2009.01.1949. PMID   19179815. S2CID   2060730.
17. "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
18. "Estrogens, Conjugated - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
19. Greer IA, Ginsberg J, Forbes C (29 December 2006). Women's vascular health. CRC Press. ISBN   978-0-340-80997-6.
20. Nezhat C, Nezhat F, Nezhat C (7 July 2008). Nezhat's Operative gynecologic laparoscopy and hysteroscopy. Cambridge University Press. ISBN   978-1-139-47200-5 . Retrieved 7 May 2015.
21. Maeda SS, Lazaretti-Castro M (March 2014). "An overview on the treatment of postmenopausal osteoporosis". Arquivos Brasileiros de Endocrinologia e Metabologia. 58 (2): 162–171. doi: 10.1590/0004-2730000003039 . PMID   24830593.
22. Majeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A, et al. (2014). "Breast cancer: major risk factors and recent developments in treatment". Asian Pacific Journal of Cancer Prevention. 15 (8): 3353–3358. doi: 10.7314/apjcp.2014.15.8.3353 . PMID   24870721.
23. 2015 Nurse's Drug Handbook. Jones & Bartlett Publishers. 14 January 2015. ISBN   978-1-284-09137-3 . Retrieved 7 May 2015.
24. Oettel M, Schillinger E (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 540–. ISBN   978-3-642-60107-1.
25. Denis LJ, Griffiths K, Kaisary AV, Murphy GP (1 March 1999). Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment. CRC Press. pp. 297–. ISBN   978-1-85317-422-3.
26. "Premarin".
27. Horský J, Presl J (1981). "Hormonal Treatment of Disorders of the Menstrual Cycle". In Horsky J, Presl J (eds.). Ovarian Function and its Disorders. Developments in Obstetrics and Gynecology. Springer Science & Business Media. pp. 309–332. doi:10.1007/978-94-009-8195-9_11. ISBN   978-94-009-8195-9.
28. Piersol GM (1975). The Cyclopedia of Medicine, Surgery, Specialties. F. A. Davis Company.
29. Morley JE, van den Berg L (5 November 1999). Endocrinology of Aging. Springer Science & Business Media. pp. 172–. ISBN   978-1-59259-715-4.
30. Shorr RI (11 April 2007). Drugs for the Geriatric Patient E-Book: Text with BONUS Handheld Software. Elsevier Health Sciences. pp. 462–. ISBN   978-1-4377-1035-9.
31. "Premarin (Conjugated estrogens) Vaginal Cream". Food and Drug Administration . Archived from the original on 26 October 2016. Retrieved 20 February 2018.
32. Bińkowska M (October 2014). "Menopausal hormone therapy and venous thromboembolism". Przeglad Menopauzalny = Menopause Review. 13 (5): 267–272. doi:10.5114/pm.2014.46468. PMC   4520375 . PMID   26327865.
33. Smith NL, Blondon M, Wiggins KL, Harrington LB, van Hylckama Vlieg A, Floyd JS, et al. (January 2014). "Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens". JAMA Internal Medicine. 174 (1): 25–31. doi:10.1001/jamainternmed.2013.11074. PMC   4636198 . PMID   24081194.
34. Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, et al. (October 2004). "Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis". JAMA. 292 (13): 1581–1587. doi: 10.1001/jama.292.13.1581 . hdl: 1887/5083 . PMID   15467060.
35. Lekovic D, Miljic P, Dmitrovic A, Thachil J (May 2017). "How do you decide on hormone replacement therapy in women with risk of venous thromboembolism?". Blood Reviews. 31 (3): 151–157. doi:10.1016/j.blre.2016.12.001. PMID   27998619.
36. Roach RE, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A (January 2013). "The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy". Journal of Thrombosis and Haemostasis. 11 (1): 124–131. doi:10.1111/jth.12060. PMID   23136837. S2CID   22306721.
37. Buchsbaum HJ (6 December 2012). The Menopause. Springer Science & Business Media. pp. 64–. ISBN   978-1-4612-5525-3.
38. Falcone T, Hurd WW (22 May 2013). Clinical Reproductive Medicine and Surgery: A Practical Guide. Springer Science & Business Media. pp. 5–6. ISBN   978-1-4614-6837-0.
39. Sanfilippo JS (January 1998). Primary Care in Obstetrics and Gynecology: A Handbook for Clinicians. Springer Science & Business Media. pp. 220, 227. ISBN   978-0-387-94739-6. Conjugated estrogens are absorbed with peak levels at 4 hours and a half-life of approximately 12 hours.
40. Cline JM (April 2007). "Assessing the mammary gland of nonhuman primates: effects of endogenous hormones and exogenous hormonal agents and growth factors". Birth Defects Research. Part B, Developmental and Reproductive Toxicology. 80 (2): 126–146. doi:10.1002/bdrb.20112. PMID   17443713.
41. Notelovitz M (March 2006). "Clinical opinion: the biologic and pharmacologic principles of estrogen therapy for symptomatic menopause". MedGenMed. 8 (1): 85. PMC   1682006 . PMID   16915215.
42. Nachtigall LE, Raju U, Banerjee S, Wan L, Levitz M (2000). "Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: associations with sex hormone-binding globulin, estradiol, and estrone levels". Menopause. 7 (4): 243–250. doi:10.1097/00042192-200007040-00006. PMID   10914617. S2CID   3076514.
43. Lauritzen C (September 1990). "Clinical use of oestrogens and progestogens". Maturitas. 12 (3): 199–214. doi:10.1016/0378-5122(90)90004-P. PMID   2215269.
44. Lauritzen C (June 1977). "[Estrogen thearpy in practice. 3. Estrogen preparations and combination preparations]" [Estrogen therapy in practice. 3. Estrogen preparations and combination preparations]. Fortschritte Der Medizin (in German). 95 (21): 1388–92. PMID   559617.
45. Wolf AS, Schneider HP (12 March 2013). Östrogene in Diagnostik und Therapie. Springer-Verlag. pp. 78–. ISBN   978-3-642-75101-1.
46. Göretzlehner G, Lauritzen C, Römer T, Rossmanith W (1 January 2012). Praktische Hormontherapie in der Gynäkologie. Walter de Gruyter. pp. 44–. ISBN   978-3-11-024568-4.
47. Knörr K, Beller FK, Lauritzen C (17 April 2013). Lehrbuch der Gynäkologie. Springer-Verlag. pp. 212–213. ISBN   978-3-662-00942-0.
48. Horský J, Presl J (1981). "Hormonal Treatment of Disorders of the Menstrual Cycle". In Horsky J, Presl J (eds.). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 309–332. doi:10.1007/978-94-009-8195-9_11. ISBN   978-94-009-8195-9.
49. Pschyrembel W (1968). Praktische Gynäkologie: für Studierende und Ärzte. Walter de Gruyter. pp. 598–599. ISBN   978-3-11-150424-7.
50. Lauritzen CH (January 1976). "The female climacteric syndrome: significance, problems, treatment". Acta Obstetricia Et Gynecologica Scandinavica. Supplement. 51: 47–61. doi:10.3109/00016347509156433. PMID   779393.
51. Lauritzen C (1975). "The Female Climacteric Syndrome: Significance, Problems, Treatment". Acta Obstetricia et Gynecologica Scandinavica. 54 (s51): 48–61. doi:10.3109/00016347509156433. ISSN   0001-6349.
52. Kopera H (1991). "Hormone der Gonaden". Hormonelle Therapie für die Frau. Kliniktaschenbücher. pp. 59–124. doi:10.1007/978-3-642-95670-6_6. ISBN   978-3-540-54554-5. ISSN   0172-777X.
53. Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of Prostatic Cancer". Cancer. 45 (Suppl 7): 1929–1936. doi:10.1002/cncr.1980.45.s7.1929. PMID   29603164.
54. Leinung MC, Feustel PJ, Joseph J (2018). "Hormonal Treatment of Transgender Women with Oral Estradiol". Transgender Health. 3 (1): 74–81. doi:10.1089/trgh.2017.0035. PMC   5944393 . PMID   29756046.
55. Ryden AB (1950). "Natural and synthetic oestrogenic substances; their relative effectiveness when administered orally". Acta Endocrinologica. 4 (2): 121–39. doi:10.1530/acta.0.0040121. PMID   15432047.
56. Ryden AB (1951). "The effectiveness of natural and synthetic oestrogenic substances in women". Acta Endocrinologica. 8 (2): 175–91. doi:10.1530/acta.0.0080175. PMID   14902290.
57. Kottmeier HL (1947). "Ueber blutungen in der menopause: Speziell der klinischen bedeutung eines endometriums mit zeichen hormonaler beeinflussung: Part I". Acta Obstetricia et Gynecologica Scandinavica. 27 (s6): 1–121. doi:10.3109/00016344709154486. ISSN   0001-6349. There is no doubt that the conversion of the endometrium with injections of both synthetic and native estrogenic hormone preparations succeeds, but the opinion whether native, orally administered preparations can produce a proliferation mucosa changes with different authors. PEDERSEN-BJERGAARD (1939) was able to show that 90% of the folliculin taken up in the blood of the vena portae is inactivated in the liver. Neither KAUFMANN (1933, 1935), RAUSCHER (1939, 1942) nor HERRNBERGER (1941) succeeded in bringing a castration endometrium into proliferation using large doses of orally administered preparations of estrone or estradiol. Other results are reported by NEUSTAEDTER (1939), LAUTERWEIN (1940) and FERIN (1941); they succeeded in converting an atrophic castration endometrium into an unambiguous proliferation mucosa with 120–300 oestradiol or with 380 oestrone.
58. Rietbrock N, Staib AH, Loew D (11 March 2013). Klinische Pharmakologie: Arzneitherapie. Springer-Verlag. pp. 426–. ISBN   978-3-642-57636-2.
59. Martinez-Manautou J, Rudel HW (1966). "Antiovulatory Activity of Several Synthetic and Natural Estrogens". In Robert Benjamin Greenblatt (ed.). Ovulation: Stimulation, Suppression, and Detection. Lippincott. pp. 243–253.
60. Herr F, Revesz C, Manson AJ, Jewell JB (1970). "Biological Properties of Estrogen Sulfates". Chemical and Biological Aspects of Steroid Conjugation. pp. 368–408. doi:10.1007/978-3-642-49793-3_8. ISBN   978-3-642-49506-9.
61. Duncan CJ, Kistner RW, Mansell H (October 1956). "Suppression of ovulation by trip-anisyl chloroethylene (TACE)". Obstetrics and Gynecology. 8 (4): 399–407. PMID   13370006.
62. Shearer RJ, Hendry WF, Sommerville IF, Fergusson JD (December 1973). "Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer". British Journal of Urology. 45 (6): 668–677. doi:10.1111/j.1464-410x.1973.tb12238.x. PMID   4359746.
63. Martinez-Manautou J, Rudel HW (1966). "Antiovulatory Activity of Several Synthetic and Natural Estrogens". In Greenblatt RB (ed.). Ovulation: Stimulation, Suppression, and Detection. Lippincott. pp. 243–253. ISBN   978-0-397-59010-0.
64. Herr F, Revesz C, Manson AJ, Jewell JB (1970). "Biological Properties of Estrogen Sulfates". Chemical and Biological Aspects of Steroid Conjugation. Springer. pp. 368–408. doi:10.1007/978-3-642-49793-3_8 (inactive 17 September 2024). ISBN   978-3-642-49506-9.
65. Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of Prostatic Cancer". Cancer. 45 (Suppl 7): 1929–1936. doi: 10.1002/cncr.1980.45.s7.1929 . PMID   29603164. S2CID   4492779.
66. Fotherby K (August 1996). "Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy". Contraception. 54 (2): 59–69. doi:10.1016/0010-7824(96)00136-9. PMID   8842581.
67. Lobo RA (5 June 2007). Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Academic Press. pp. 771–. ISBN   978-0-08-055309-2.
68. Notelovitz M, van Keep PA (6 December 2012). The Climacteric in Perspective: Proceedings of the Fourth International Congress on the Menopause, held at Lake Buena Vista, Florida, October 28–November 2, 1984. Springer Science & Business Media. pp. 395–. ISBN   978-94-009-4145-8.
69. Seidel GE (1974). Gonadotrophins: Current Research. Ardent Media. pp. 157–. ISBN   978-0-8422-7205-6.
70. Punnonen R, Vilska S, Grönroos M, Rauramo L (December 1980). "The vaginal absorption of oestrogens in post-menopausal women". Maturitas. 2 (4): 321–326. doi:10.1016/0378-5122(80)90034-1. PMID   7231202.
71. Honjo H, Kitawaki J, Itoh M, Yasuda J, Iwasaku K, Urabe M, et al. (1987). "Serum and urinary estrone sulfate during the menstrual cycle, measured by a direct radioimmunoassay, and fate of exogenously injected estrone sulfate". Hormone Research. 27 (2): 61–68. doi:10.1159/000180788. PMID   3653846.
72. Hammond CB, Maxson WS (January 1982). "Current status of estrogen therapy for the menopause". Fertility and Sterility. 37 (1): 5–25. doi:10.1016/S0015-0282(16)45970-4. PMID   6277697.
73. Bhavnani BR, Tam SP, Lu X (October 2008). "Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta". Endocrinology. 149 (10): 4857–70. doi:10.1210/en.2008-0304. PMID   18599548.
74. Feldberg GD, Ladd-Taylor M, Li A (2003). Women, Health and Nation: Canada and the United States Since 1945. McGill-Queen's Press - MQUP. pp. 103–. ISBN   978-0-7735-2501-6.
75. Schachter B, Marrian GF (1938). "The isolation of estrone sulfate from the urine of pregnant mares". Journal of Biological Chemistry. 126 (2): 663–669. doi: 10.1016/S0021-9258(18)73874-X .
76. Kling J (October 2000). "The Strange Case of Premarin". Modern Drug Discovery. 3 (8): 46–52.
77. "Federal register [microform]". Washington : [Office of the Federal Register, National Archives and Records Service, General Services Administration : Distributed by the Supt. of Docs., U.S. G.P.O.] 3 June 1972 – via Internet Archive.
78. National Institutes of Health Consensus Development Conference Statement. 2–4 April 1984 Osteoporosis Archived 21 November 2005 at the Wayback Machine
79. Food and Drug Administration. 5 May 1997 Conjugated Estrogens - Letter from Dr. Janet Woodcock: Approvability of a Synthetic Generic Version of Premarin
80. Panay N, Briggs P, Kovacs G (20 August 2015). Managing the Menopause. Cambridge University Press. pp. 118–. ISBN   978-1-107-45182-7. Premarin (Pregnant Mares Urine) was introduced in Canada in 1941, in the USA in 1942 and in the UK in 1956.
81. Dominus S (1 February 2023). "Women Have Been Misled About Menopause". The New York Times. ISSN   0362-4331 . Retrieved 7 February 2023. Every woman has the right — indeed the duty — to counteract the chemical castration that befalls her during her middle years," the gynecologist Robert Wilson wrote in 1966. The U.S. Food and Drug Administration approved the first hormone-therapy drug in 1942, but Wilson's blockbuster book, "Feminine Forever," can be considered a kind of historical landmark...Within a decade of the book's publication, Premarin — a mix of estrogens derived from the urine of pregnant horses — was the fifth-most-prescribed drug in the United States. (Decades later, it was revealed that Wilson received funding from the pharmaceutical company that sold Premarin.)
82. "ChemIDplus - 12126-59-9 - QTTMOCOWZLSYSV-QWAPEVOJSA-M - Estrogens, conjugated [USP:JAN] - Similar structures search, synonyms, formulas, resource links, and other chemical information".
83. Alexander IM (2012). "The history of hormone therapy use and recent controversy related to heart disease and breast cancer arising from prevention trial outcomes". Journal of Midwifery & Women's Health. 57 (6): 547–557. doi:10.1111/j.1542-2011.2012.00247.x. PMID   23217066.
84. Davis SR, Dinatale I, Rivera-Woll L, Davison S (May 2005). "Postmenopausal hormone therapy: from monkey glands to transdermal patches". The Journal of Endocrinology. 185 (2): 207–222. doi: 10.1677/joe.1.05847 . PMID   15845914.
85. Smith AL, Wein AJ (December 2010). "Estrogen replacement therapy for the treatment of postmenopausal genitourinary tract dysfunction". Discovery Medicine. 10 (55): 500–510. PMID   21189221.
86. Hochadel MA, Avorn J (1 January 2007). The AARP Guide to Pills: Essential Information on More Than 1,200 Prescription and Nonprescription Medications, Including Generics. Sterling Publishing Company Incorporated. pp. 235–. ISBN   978-1-4027-4446-4.
87. Ziel HK, Finkle WD (December 1975). "Increased risk of endometrial carcinoma among users of conjugated estrogens". The New England Journal of Medicine. 293 (23): 1167–1170. doi:10.1056/NEJM197512042932303. PMID   171569.
88. McDonald TW, Annegers JF, O'Fallon WM, Dockerty MB, Malkasian GD, Kurland LT (March 1977). "Exogenous estrogen and endometrial carcinoma: case-control and incidence study". American Journal of Obstetrics and Gynecology. 127 (6): 572–580. doi:10.1016/0002-9378(77)90351-9. PMID   190887.
89. Singer N, Wilson D (12 December 2009). "Menopause, as Brought to You by Big Pharma". New York Times.
90. Brunner RL, Gass M, Aragaki A, Hays J, Granek I, Woods N, et al. (Womens Health Initiative Investigators) (September 2005). "Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial" (PDF). Archives of Internal Medicine. 165 (17): 1976–1986. doi: 10.1001/archinte.165.17.1976 . PMID   16186467.
91. "Earnings Results for the 2006 Fourth Quarter and Full Year" (PDF) (Press release). Wyeth. Archived from the original (PDF) on 27 November 2007. Retrieved 20 February 2018.
92. "Pfizer Statement on Prempro". Indy News Channel. 24 November 2009. Archived from the original on 23 February 2012.
93. Feeley J (24 February 2010). "Pfizer wins trial over claim Prempro caused cancer". Bloomberg.
94. "Pfizer properly warned about Prempro risks, jury finds". 3 December 2010.
95. "Legal Intelligencer: Philadelphia jury returns defense verdict in HRT case, Amaris Elliott Engel".
96. Morrison K (19 January 2004). "The HRT horses". msnbc.com.

Further reading

• Bhavnani BR (November 1988). "The saga of the ring B unsaturated equine estrogens". Endocrine Reviews. 9 (4): 396–416. doi:10.1210/edrv-9-4-396. PMID   3065072.
• Ansbacher R (April 1993). "Bioequivalence of conjugated estrogen products". Clinical Pharmacokinetics. 24 (4): 271–274. doi:10.2165/00003088-199324040-00001. PMID   8387902. S2CID   7681617.
• O'Connell MB (September 1995). "Pharmacokinetic and pharmacologic variation between different estrogen products". Journal of Clinical Pharmacology. 35 (9S): 18S–24S. doi:10.1002/j.1552-4604.1995.tb04143.x. PMID   8530713. S2CID   10159196.
• Egarter C, Geurts P, Boschitsch E, Speiser P, Huber J (April 1996). "The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women". Acta Obstetricia et Gynecologica Scandinavica. 75 (4): 386–393. doi:10.3109/00016349609033337. PMID   8638462. S2CID   44498140.
• Bhavnani BR (January 1998). "Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism". Proceedings of the Society for Experimental Biology and Medicine. 217 (1): 6–16. doi:10.3181/00379727-217-44199. PMID   9421201. S2CID   45177839.
• Gruber DM, Huber JC (December 1999). "Conjugated estrogens--the natural SERMs". Gynecological Endocrinology. 13 (Suppl 6): 9–12. PMID   10862263.
• Campagnoli C, Ambroggio S, Biglia N, Sismondi P (December 1999). "Conjugated estrogens and breast cancer risk". Gynecological Endocrinology. 13 (Suppl 6): 13–19. PMID   10862264.
• Bhavnani BR (June 2003). "Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's". The Journal of Steroid Biochemistry and Molecular Biology. 85 (2–5): 473–482. doi:10.1016/S0960-0760(03)00220-6. PMID   12943738. S2CID   45552896.
• Ortmann J, Traupe T, Vetter W, Barton M (May 2004). "[Postmenopausal hormone replacement therapy and cardiovascular risk: role of conjugated equine estrogens and medroxyprogesterone acetate]". Praxis (in German). 93 (21): 904–914. doi:10.1024/0369-8394.93.21.904. PMID   15216975.
• Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID   16112947. S2CID   24616324.
• Kurabayashi T (November 2007). "[New evidence of conjugated estrogen and 17beta-estradiol for treatment and prevention of osteoporosis]". Nihon Rinsho. Japanese Journal of Clinical Medicine (in Japanese). 65 (Suppl 9): 369–373. PMID   18161134.
• Lamba G, Kaur H, Adapa S, Shah D, Malhotra BK, Rafiyath SM, et al. (June 2013). "Use of conjugated estrogens in life-threatening gastrointestinal bleeding in hemodialysis patients--a review". Clinical and Applied Thrombosis/Hemostasis. 19 (3): 334–337. doi:10.1177/1076029612437575. PMID   22411999. S2CID   30468265.
• Mirkin S, Komm BS, Pickar JH (January 2014). "Conjugated estrogens for the treatment of menopausal symptoms: a review of safety data". Expert Opinion on Drug Safety. 13 (1): 45–56. doi:10.1517/14740338.2013.824965. PMID   23919270. S2CID   24379298.
• Bhavnani BR, Stanczyk FZ (July 2014). "Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action". The Journal of Steroid Biochemistry and Molecular Biology. 142: 16–29. doi:10.1016/j.jsbmb.2013.10.011. PMID   24176763. S2CID   1360563.
• Mattison DR, Karyakina N, Goodman M, LaKind JS (September 2014). "Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: a review of the data and identification of knowledge gaps". Critical Reviews in Toxicology. 44 (8): 696–724. doi:10.3109/10408444.2014.930813. PMID   25099693. S2CID   11212469.

External links

• WHI Follow-up Study Confirms Health Risks of Long-Term Combination Hormone Therapy Outweigh Benefits for Postmenopausal Women NIH press release, 4 March 2008